Zydus gets USFDA tentative nod for Carbidopa, Levodopa Extended-Release Capsules

Ahmedabad: Zydus Cadila has received tentative approval from the USFDA to market Carbidopa and Levodopa Extended-Release Capsules in the strengths of 23.75 mg/95 mg, 36.25 mg/145 mg, 48.75 mg/195 mg, and 61.25 mg/245 mg.

This combination medication is indicated for the treatment of Parkinson's disease or Parkinson-like symptoms (such as shakiness, stiffness, and difficulty moving) and will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.

The group now has 282 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.

Read also: Zydus, XOMA enter into licensing agreement for IL-2-Based Immuno-Oncology Therapy

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

Read also: Cadila Healthcare BOD approves transfer of Animal Healthcare Business to Zydus Animal Health and Investments Limited